A. Corey

发表

Phase I study of a fully human monoclonal antibody to the tumor necrosis factor-related apoptosis-inducing ligand death receptor 4 (TRAIL-R1) in subjects with advanced solid malignancies or non-Hodgkin's lymphoma (NHL).

A. Oza, S. Hotte, M. Maclean, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

HGS-ETR1, a fully human monoclonal antibody to the tumor necrosis factor-related apoptosis-inducing ligand death receptor 1 (TRAIL-R1) in patients with advanced solid cancer: Results of a phase 1 trial

A. Oza, H. Hirte, S. Hotte, 2005 .

HGS-ETR1, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: Results of a phase 1 and PK study.

L. Chow, R. Cohen, D. Gustafson, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1.

A. Tolcher, M. von Mehren, T. Mays, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase 1 Study of Mapatumumab (Fully Human Monoclonal Antibody to TRAIL-R1) in Patients with Advanced Solid Malignancies

A. Oza, H. Hirte, L. Siu, 2008, Clinical Cancer Research.

Estimation of Time Period for Effective Human Inhalational Anthrax Treatment Including Antitoxin Therapy

D. Hanfling, Lewis Rubinson, A. Corey, 2017, PLoS currents.

Added Benefit of Raxibacumab to Antibiotic Treatment of Inhalational Anthrax

T. Migone, D. Vasconcelos, G. Meister, 2014, Antimicrobial Agents and Chemotherapy.

Bacillus anthracis Protective Antigen Kinetics in Inhalation Spore-Challenged Untreated or Levofloxacin/Raxibacumab-Treated New Zealand White Rabbits

M. Fiscella, T. Migone, Cecil Chen, 2013, Toxins.

Raxibacumab for the treatment of inhalational anthrax.

S. Ullrich, J. Mott, T. Migone, 2009, The New England journal of medicine.

Azimilide dihydrochloride, a novel antiarrhythmic agent.

R. Brooks, A. Moore, A. Corey, 1998, The American journal of cardiology.

Effect of mild and moderate hepatic impairment on azimilide pharmacokinetics following single dose oral administration.

G. Thompson, Eileen C King, A. Corey, 2004, Journal of pharmaceutical sciences.

Phase I and pharmacokinetic study of HGS-ETR2, a human monoclonal antibody to TRAIL R2, in patients with advanced solid malignancies

R. Plummer, J. Bono, A. Calvert, 2005 .

Influence of Coadministration on the Pharmacokinetics of Azimilide Dihydrochloride and Digoxin

G. Thompson, R. D. Toothaker, A. Corey, 2005, Journal of clinical pharmacology.

Effect of Age and Gender on Azimilide Pharmacokinetics After a Single Oral Dose of Azimilide Dihydrochloride

P. Bryson, S. Griffith, A. Corey, 1997, Journal of clinical pharmacology.

Effect of Multiple Cilostazol Doses on Single Dose Lovastatin Pharmacokinetics in Healthy Volunteers

A. Corey, S. Mallikaarjun, J. Brisson, 1999, Clinical pharmacokinetics.

Azimilide Pharmacokinetics following Intravenous and Oral Administration of a Solution and Capsule Formulation

G. Thompson, A. Corey, J. Nesbitt, 1999, Journal of clinical pharmacology.

Effect of severe renal impairment on the pharmacokinetics of azimilide following single dose oral administration.

G. Thompson, A. Corey, J. Powell, 2002, British journal of clinical pharmacology.

Comparative oral bioavailability of azimilide dihydrochloride in the fed and fasted states.

G. Thompson, A. Corey, J. Nesbitt, 2000, British journal of clinical pharmacology.

Pharmacokinetics and Pharmacodynamics following Intravenous Doses of Azimilide Dihydrochloride

A. Corey, J. Brum, J. Agnew, 1999, Journal of clinical pharmacology.

Population Pharmacokinetics and Exposure‐Response of Albinterferon Alfa‐2b

James A. Rogers, M. Gastonguay, Cecil Chen, 2012, Journal of clinical pharmacology.

Phase 1 and Pharmacokinetic Study of Lexatumumab in Patients with Advanced Cancers

R. Plummer, I. Judson, S. Kaye, 2007, Clinical Cancer Research.

Phase I assessment of the pharmacokinetics, metabolism, and safety of emitefur in patients with refractory solid tumors.

J. Nemunaitis, K. Sekar, R. Pazdur, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

APhase 1 Study of Mapatumumab ( Fully HumanMonoclonal Antibody toTRAIL-R 1 ) in Patients with Advanced Solid Malignancies Se ¤

A. Oza, H. Hirte, L. Siu, 2008 .

30 A phase I clinical trial of HGS-ETR1, an agonist monoclonal antibody to TRAIL-R1, in patients with advanced solid tumors

A. Tolcher, M. Mita, E. Rowinsky, 2004 .

197 A phase I and pharmacokinetic (PK) study of an agonistic, fully human monoclonal antibody, HGS-ETR2, to the TNF-alpha related apoptosis inducing ligand receptor 2 (TRAIL R2) in patients with advanced cancer

R. Plummer, J. Bono, G. Attard, 2004 .

A phase I and pharmacokinetic study of HGS-ETR1(TRM-1), a human monoclonal agonist-antibody to TRAIL R1, in patients with advanced solid tumors

A. Tolcher, L. Weiner, A. Patnaik, 2004 .

A phase I study with the agonistic TRAIL-R1 antibody, mapatumumab, in combination with gemcitabine and cisplatin

S. Sleijfer, J. Verweij, J. Gietema, 2008 .

Azimilide pharmacokinetics and pharmacodynamics upon multiple oral dosing

A. Corey, R. Karam, S. Marcello, 1999, Biopharmaceutics & drug disposition.